Publication at First Faculty of Medicine |
2016
Abstract
The inhibitors of sodium-glucose cotransporter (SGLT2) open new époque in the treatment of diabetes because they decrease plasma glucose and improve diabetes control by different mechanism than other antidiabetic drugs. Besides the effects of other antidiabetic drugs influencing pancreas or a target organ for the insulin action, the SGLT2 inhibition causes that kidneys are involved in the regulation of glucose homeostasis.